1,423 results on '"Penel, Nicolas"'
Search Results
2. Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
3. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
4. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
5. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
6. Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trial
7. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort
8. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
9. Why do second-cycle medical students choose oncology? A literature overview
10. A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
11. Doit-on prendre en compte le stress informationnel de l’oncologue médical ?
12. ASO Visual Abstract: Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
13. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
14. Apport de l’IRM corps entier au bilan initial du liposarcome myxoïde
15. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
16. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
17. Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy
18. Senescence Induced by UVB in Keratinocytes Impairs Amino Acids Balance
19. Regorafenib for the Treatment of Sarcoma
20. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age
21. Gestion des toxicités induites par les inhibiteurs des points de contrôle immunitaire en oncologie : cartographie des pratiques françaises
22. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients
23. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT
24. Myositis ossificans circumscripta after surgery and radiotherapy and during sunitinib treatment: a case report
25. Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study
26. La phase socle en oncologie : retour d’expérience sur les trois premières années d’application de la réforme du troisième cycle
27. L’année 2021 dans tous ses états : une synthèse digérée
28. Epithelioid Hemangioendothelioma
29. Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial
30. Guide sur le rôle du « Docteur Junior » en oncologie médicale
31. La « Limitation et/ou arrêt des thérapeutiques » (LAT) en oncologie face à une situation aigüe : historique et aspects réglementaires en France
32. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study
33. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
34. Que retenir de l’année 2020 ?
35. Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)
36. Quoi de neuf dans la prise en charge des tumeurs fibreuses solitaires/hémangiopéricytomes des méninges ?
37. Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
38. Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies
39. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
40. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
41. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial
42. Traitements systémiques des fibromatoses agressives chez l’adulte et l’enfant : niveau de preuve et questions en suspens
43. Florilège des actualités oncologiques internationales en 2019
44. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy
45. Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF)
46. PD-L1 Expression and its Prognostic Value in Metastatic Papillary Renal Cell Carcinoma: Results from a GETUG Multicenter Retrospective Cohort
47. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial
48. Determinants of the access to remote specialised services provided by national sarcoma reference centres
49. Home hospitalization for palliative cancer care: factors associated with unplanned hospital admissions and death in hospital
50. Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.